lonza.com

Fiera Milano, Italy Lonza booth: 6F2 Lonza is excited to announce the participation in CPHI Milan 2026, the world's leading pharmaceutical event! Join us in Milan, Italy, as we connect with industry leaders and showcase our comprehensive contract manufacturing services that are shaping the future of pharmaceutical development and manufacturing. At Lonza, we partner with you to transform therapeutic discoveries into lifesaving and life-enhancing treatments.

Basel, Switzerland, 10 September 2026 – Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced today plans to further strengthen its significant US presence by constructing a large-scale commercial spray-drying facility in Bend, Oregon. The investment will establish Lonza as the leading CDMO provider of commercial-scale spray-drying PSD-4 capacity in the US.

Lonza Appoints Samanta Cimitan as Chief Commercial Officer Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President and Member of the Extended Executive Committee by 1 January 2027. Samanta brings extensive business leadership experience across the CDMO industry, currently serving as Chief Executive Officer of the Celonic Group.

Lonza Delivered Strong H1 2026 Performance Across All Business Platforms and Upgrades Full-Year 2026 Margin Outlook In H1 2026, Lonza1 delivered sales of CHF 3.4 billion with +16.0% CER2 sales growth The CORE EBITDA margin significantly expanded by +4.4ppts versus H1 2025, reaching 34.8% with a CORE EBITDA of CHF 1.2 billion Free Cash Flow (FCF) generation improved further, delivering CHF 0.4 billion Sustained commercial demand continued across technologies and geographies, including the...

Lonza erzielte im ersten Halbjahr 2026 starke Ergebnisse über alle Geschäftsplattformen hinweg und erhöht den Margenausblick für das Gesamtjahr 2026 Im ersten Halbjahr 2026 erzielte Lonza1 einen Umsatz von CHF 3.4 Milliarden bei einem Umsatzwachstum in kWk2 von +16.0% Die Kern-EBITDA-Marge stieg gegenüber dem ersten Halbjahr 2025 deutlich um +4.4 Prozentpunkte und erreichte 34.8%.

Basel, Switzerland, 1 July 2026 – Lonza, the world’s leading contract development and manufacturing organization (CDMO), today announced an expanded strategic collaboration with a leading US-based biopharmaceutical company. The expansion adds two biologics programs to be produced commercially, with the option for two more, and further strengthens an established multi-year relationship, including long-term commitments across a broad portfolio of multiple biologics programs.

Basel, Switzerland, 30 June 2026 – Lonza, the world’s leading contract development and manufacturing organization (CDMO), today announced plans to enhance its drug-linker center of excellence and expand payload-linker manufacturing capacity at its Visp site.

Basel, Switzerland, 23 June 2026 – Prior to the release of its Half-Year 2026 results on 22 July, Lonza has published restated Half-Year 2025 financial information reflecting the classification of its CHI business as discontinued operations, in line with its Full-Year 2025 reporting. In December 2024, Lonza announced its intention to divest the CHI business. As a result, the CHI results were reported as discontinued operations for the Full-Year 2025.

Basel, Switzerland, 9 June 2026 – Lonza today announced the appointment of Hans Trees as Global Head of Communications, Senior Vice President and member of the Extended Executive Committee. Hans will join Lonza on 1 September 2026 and succeed David Carter, who has led Lonza’s Communications function since 2019. Hans is a seasoned communications executive with broad experience across communications, strategy and business leadership in global organizations.

All Board members standing for re-election were re-elected, each for a further term in office until the completion of the AGM 2027. The following Board members stood for re-election: Jean-Marc Huët, Juan Andres, Eric Drapé, Marion Helmes, Angelica Kohlmann, Christoph Mäder and David Meline. Shareholders approved the election of Claudia Süssmuth-Dyckerhoff, Sami Atiya and Stephen Fry as new Board members, each for a term in office until the completion of the AGM 2027.